

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Chi Sing et al.
SERIAL NO.: 09/966,611
FILING DATE: 09/27/01
TITLE: ABSORBABLE SPONGE WITH CONTRASTING AGENT
EXAMINER: Baxter, Jessica R
ART UNIT: 3731

T-H
2-10-04
#26/IDS

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as First Class
Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
on the date printed below:

Date: January 27, 2004

Name: _____

Ruth Rodriguez

COMMISSIONER FOR PATENTS
P.O. Box 1450, ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached, may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§ 1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

02/04/2004 HVUONG1 00000100 09966611

02 FC:1806

180.00 OP

This Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

I

This statement is filed pursuant to:

() 37 C.F.R. § 1.97(b).

This information disclosure statement is filed either (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; (3) before the mailing date of a first office action on the merits, or (4) before the mailing of a first office action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114, whichever event occurs last.

Accordingly, this information disclosure statement requires no fee and no certification.

(X) 37 C.F.R. § 1.97(c).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97 (b), but before the mailing date of either (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application.

Accordingly, this information disclosure statement requires either the fee specified in 37 C.F.R. § 1.17 (p) for submission of an information disclosure statement under 37 C.F.R. § 1.97 (c) (\$180); or a certification according to 37 C.F.R. § 1.97 (e).

() 37 C.F.R. § 1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97 (c).

Accordingly, this information disclosure statement requires the fee specified in 37 C.F.R. § 1.17 (p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d) (\$180), and a certification according to 37 C.F.R. § 1.97(e).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II

- () No fee is due.
- (X) The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) is enclosed (\$180).

Please charge any additional required fee or credit any overpayment to our deposit account number 50-1698.


III

Pursuant to 37 C.F.R. § 1.97(e) , I certify:

- ☒ No certification is necessary.
- () (1) Each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information statement; or
- () (2) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of the statement.

Respectfully submitted,
THELEN REID & PRIEST LLP

Dated: January 27, 2004


Adrienne Yeung
Reg. No. 44,000

THELEN REID & PRIEST LLP
P.O. Box 640640
San Jose, CA 95164-0640
(408) 292-5800 direct dial
(408) 287-8040 direct fax

Form PTO 1449 (Rev. 2-32)				U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 034298-000121		Serial No. 09/966,611	
Information Disclosure Statement by Applicant						Applicant: Chi Sing et al.			
(Use several sheets if necessary)						Filed: 09/27/01		Group: 3731	
U.S. Patent Documents									
Init.		Document No.	Date	Name	Class	Subclass	Filing Date		
		2002/0042378	4/02	Reich et al					
		2003/0088271	5/03	Cragg et al					
		2,874,776	2/59	H.E. Hooe					
		2,370,319	2/45	J.G. Lippincott					
		3,358,689	12/64	J.L. Higgins					
		3,411,505	11/68	P.D. Nobis					
		3,736,939	6/73	Glenn Taylor					
		4,219,026	8/80	Terry Layton					
		4,224,945	9/80	Jonathan Cohen					
		4,405,314	9/83	Constantin Cope					
		4,573,576	3/86	Thomas Krol					
		4,644,649	2/87	Seaman et al					
		4,699,616	10/87	Norwak et al					
		4,832,688	5/89	Sagae et al					
		4,839,204	6/89	Yoshino					
		4,869,143	9/89	Merrick et al					
Foreign Documents									
Init.		Document No.	Date	Country	Class	Subclass	Translation		
		WO 97/09934	20.03.97	PCT			Yes	No	
		WO 95/32679	07.12.95	PCT			X		
							X		
Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)									
		Correll et al, "A New Physiologically Absorbable Sponge" pg. 233-235							
		Correll et al., "Biologic Investigation of a New Absorbable Sponge" pg. 585-589							
		Journal of Interventional Cardiology, Volume 5 Number 2 June 1992, Futura Publishing Company, Inc.							
		Kassell, et al. "Size of Intracranial Aneurysms" vol. 12 no. 3 1983							
Examiner						Date Considered			
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.									

FEB 02 2004

Form PTO 144 (Rev. 2-92)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 034298-000121	Serial No. 09/966,611
-----------------------------	--	-----------------------------------	--------------------------

Information Disclosure Statement by Applicant

Applicant: Chi Sing et al.

(Use several sheets if necessary)

Filed: 09/27/01

Group: 3731

U.S. Patent Documents

Init.	Document No.	Date	Name	Class	Subclass	Filing Date
	5,049,138	9/91	Cevalier et al.			
	5,129,889	7/92	Hahn et al.			
	5,192,290	3/93	Said Hilal			
	5,219,899	6/93	Panster et al			
	5,232,453	8/93	Plass et al.			
	5,254,105	10/93	John Haaga			
	5,320,639	6/94	James Rudnick			
	5,342,388	8/94	Sonia Toller			
	5,350,399	9/94	Erlebacher			
	5,352,211	10/94	William Merskelly			
	5,399,361	3/95	Song et al			
	5,447,502	9/95	John Haaga			
	5,458,570	10/95	James W. May Jr.			
	5,545,175	8/96	Abidin et al			
	5,571,168	11/96	Connie Toro			
	5,601,601	2/97	Tal et al			
	5,620,461	4/97	Van De Moer et al			
	5,674,346	10/97	Kundel			
	5,707,393	1/98	Kensey			
	5,931,165	8/99	Reich et al			

RECEIVED

FEB 06 2004

TECHNOLOGY CENTER R3700

Foreign Documents

							Translation	
Init.	Document No.	Date	Country	Class	Subclass		Yes	No


Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)

	Schievink, "Intracranial Aneurysms", the New England Journal of Medicine, 1/2/97
	Szikora et al. "Combined Use of Stents and Coils to Treat Experimental Wide-Necked Carotid Aneurysms: Preliminary Results" AJNR Am J Neuroradiol 15:091-1102, Jue 1997
	Szikora et al. "Endovascular Treatment of Experimental Aneurysms with Liquid Polymers: The Protective Potential of Stents" Neurosurgery, vol. 38, No. 2, February 1996

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

[illegible]



Atty. Docket No.
034298-000121

Serial No.
09/966,611

Information Disclosure Statement by Applicant

Applicant: Chi Sing et al.

(Use several sheets if necessary)

Filed: 09/27/01

Group: 3731

U.S. Patent Documents

TECHNOLOGY CENTER B3700

Foreign Documents


Translation

Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



Form PTO 146 (Rev. 10-1-99)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 034298-000121	Serial No. 09/966,611
--------------------------------	--	-----------------------------------	--------------------------

Information Disclosure Statement by Applicant

Applicant: Chi Sing et al.

(Use several sheets if necessary)

Filed: 09/27/01

U.S. Patent Documents

Init.	Document No.	Date	Name	Class	Subclass	Filing Date

RECEIVED

FEB 06 2004

TECHNOLOGY CENTER R3700

Foreign Documents

							Translation	
Init.	Document No.	Date	Country	Class	Subclass		Yes	No
	WO 94/28800	22.12.94	PCT				X	
	WO 95/28124	26.10.95	PCT				X	
	WO 95/32671	07.12.95	PCT				X	
	WO 95/32669	07.12.95	PCT				X	
	WO 96/24290	15.08.96	PCT				X	
	WO 98/06346	19.02.98	PCT				X	
	WO 99/66834	29.12.99	PCT				X	

Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner

Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.